HOME¥NEWS&EVENTS SYMPOSIA RESEARCH / GRANT OTHER ACTIVITIES CONTACT HIRF
 
About HIRF
  1. Mission
  2. Management
  3. History
  4. Affiliates

About ICVS

  • 2001 Tokyo
  • 2003 Beijing
  • 2004 London
  • 2006 Washington DC
  • 2007 Vienna
  • 2008 New York
Research
Grant Programs
  • Clinical Trials
  • Education
  • Training
  • Publication

Recommended Links

Contact HIRF

International Cancer Vaccine Symposium
In London 2004
gClinical and Laboratory Advances in Cancer Vaccines and Immunotherapiesh
Friday-Sunday 12-14 November 2004
Royal Society of Medicine, London, the United Kingdom

FRIDAY 12 NOVEMBER 2004

18:30 Speakers' Reception and Buffet at RSM

SATURDAY 13 NOVEMBER 2004

8:30 Coffee and Registration
9:10 Welcome Address
Sir John Lilleyman, President, RSM
Dr. Kenichiro Hasumi, Chairman, HIRF

SESSION 1: KEYNOTE SPEAKERS
Chair: Dr Lowell Harmison, PHS (RET.), USA

9:30 Cancer: a Global Disease
Dr. Yank D. Coble, President, the World Medical Association
10:00 A UK Perspective
Prof. Karol Sikora, Imperial College School of Medicine

SESSION 2: TARGETING VIRAL ANTIGENS
Chair: Prof. Angus Dalgleish, St Georgefs Hospital Medical School

11:00 HPV Virus-like Particles and Vaccine Development
Dr. Douglas Lowy, National Cancer Institute/NIH, USA
11:30 Therapeutic HPV vaccines
Prof. Peter Stern, Paterson Institute, Manchester
12:00 Vaccines Targeting EB Positive Malignancies
Prof. Alan Rickinson, The University of Birmingham

SESSION 3: APPROACHES TO IMMUNOTHERAPY AND CLINICAL TRIALS
Chair: Prof. Robert Hawkins, University of Manchester

13:30 Critical Issues in the Development of Cancer Vaccines
Dr. Jeffrey Schlom, National Cancer Institute/NIH, USA
14:00 Overcoming the tumour Challenge to Cancer Vaccines by Focusing on Premalignant Disease
Dr. Olivera Finn, University of Pittsburgh, USA
14:30 DNA Vaccines
Dr. Christian Ottensmeier, University of Southampton
15:00 Immunostimulatory Antibodies
Prof. Martin Glennie, University of Southampton
15:30 The Role of Allogeneic Cells and Dendritic Cell Antigen Presentation in the Development of Effective Cancer Vaccines
Prof. Angus Dalgleish, St George's Hospital Medical School

SESSION 4: REGULATORY ISSUES IN CLINICAL TRIALS
Chair: Dr. Lowell Harmison, PHS (RET.), USA

16:30 The US Perspective
Dr. Lowell Harmison, Dr. Douglas Lowy, Dr. Jeffrey Schlom, Dr. Jeffrey Weber
16:50 The UK Perspective
Dr. Brian Davies, Clinical Trials Consultant, MHRA
17:10 The French Perspective
Dr. Jean-Ybes Bonnefoy, Director Cancerople Lyon Rhone-Alpes, France
17:30 The Russian Perspective
Prof. Andrei Kozlov, St. Petersburg University, Russia
17:30 The Russian Perspective
Prof. Andrei Kozlov, St. Petersburg University, Russia
Panel Discussion
All Session 4 Speakers plus Professor Schuler and Professor Stingl
18:00 Close of Day One
18:30 Dinner for All Attendees at RSM

SUNDAY 14 NOVEMBER 2004

SESSION 5: DENDRITIC CELLS
Chair: Dr. Kayo Inaba, Kyoto University, Japan

9:15 Dendritic Cells as Targets for Immunotherapy
Dr. Ralph Steinman, Rockefeller University, USA
9:45 Dendritic Cell-Based Vaccination Against Cancer
Prof. Gerold Schuler, University of Erlagen, Germany
10:15 Dendritic Cell Vaccine in Melanoma
Dr. Jacques Banchereau, Baylor Institute for Immunology Research, USA
11:15 Experimental Strategies to Enhance the Potency of Dendritic Cell-Based Cancer Vaccines for Clinical Use
Dr. James Mule, Moffitt Cancer Centre, USA
11:45 Arming dendritic cells for Cancer Immunotherapy
Prof. Laurence Young, The University of Birmingham
12:15 Immunostimulation via the Skin - a Means of Cancer Immunotherapy
Prof. Georg Stingl, University of Vienna Medical School, Austria

SESSION 6: IMMUNOTHERAPEUTIC TARGETS
Chair: Prof. Tim Elliott, University of Southampton

13:45 Exploiting the Intentional Induction of Autoimmune Reactivity to Treat Metastatic Disease
Dr. Richard Vile, Mayo Clinic, USA
14:15 Clinical Evaluation of 5T4 as a Novel Target for Cancer Immunotherapy
Prof. Robert Hawkins, University of Manchester
14:45 Immunodominance: gLessons from Clinical Traials in Melanoma Patientsh
Prof. Vincenzo Cerundolo, University of Oxford

SESSION 7: IMMUNE RESPONSES
Chair: Prof. Peter Johnson, University of Southampton

15:45 Infusion of Anti-CD3/Anti-CD28 Expanded T-cells Post-Stem Cell Treatment Alters an Immune Response to a Pre-Transplant Vaccine: Investigation of the Possible Role of Cytokines/Chemokines in this Response
Dr. Dean Mann, University of Maryland, USA
15:15 Precision Guiding of Cytolytic T-lymphocyte Responses
Dr. Cornelis Melief, University Hospital Leiden, the Netherlands
16:45 New Paradigms in Antigen Specific Approaches to Melanoma
Dr. Jeffrey Weber, Norris Comprehensive Cancer Center, University of Southern California, USA

SESSION 8: SUMMARY
Chair: Prof. Robin Williamson, Dean, RSM

17:15 Summary Talk
Prof. Hans Wigzell, Karolinska Institutet, Sweden

CLOSING

17:45 Closing Words

18:00 Close of Symposium

19:00 Speakersf Dinner